推荐产品
等級
pharmaceutical primary standard
API 家族
fluocinolone
製造商／商標名
EDQM
mp
267-269 °C (lit.)
應用
pharmaceutical (small molecule)
形式
neat
SMILES 字串
CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO
InChI
1S/C24H30F2O6/c1-20(2)31-19-9-13-14-8-16(25)15-7-12(28)5-6-21(15,3)23(14,26)17(29)10-22(13,4)24(19,32-20)18(30)11-27/h5-7,13-14,16-17,19,27,29H,8-11H2,1-4H3/t13-,14-,16-,17-,19+,21-,22-,23-,24+/m0/s1
InChI 密鑰
FEBLZLNTKCEFIT-VSXGLTOVSA-N
基因資訊
human ... NR3C1(2908)
正在寻找类似产品? 访问 产品对比指南
一般說明
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
應用
Fluocinolone acetonide EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
包裝
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他說明
Sales restrictions may apply.
訊號詞
Warning
危險聲明
危險分類
Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
標靶器官
Respiratory system
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
Benjamin P Nicholson et al.
American journal of ophthalmology, 154(6), 969-973 (2012-09-18)
To characterize the phenomenon of dissociation of the 2 components of the sustained-release fluocinolone acetonide implant (Retisert; Bausch & Lomb) during removal or exchange procedures, or both, and to evaluate outcomes after these events. Retrospective, observational case series. Retrospective review
Raymond Iezzi et al.
Biomaterials, 33(3), 979-988 (2011-11-04)
Retinal neuroinflammation, mediated by activated microglia, plays a key role in the pathogenesis of photoreceptor and retinal pigment epithelial cell loss in age-related macular degeneration and retinitis pigmentosa. Targeted drug therapy for attenuation of neuroinflammation in the retina was explored
Peter A Campochiaro et al.
Ophthalmology, 119(10), 2125-2132 (2012-06-26)
To assess long-term efficacy and safety of intravitreal inserts releasing 0.2 μg/d (low dose) or 0.5 μg/d (high dose) fluocinolone acetonide (FAc) in patients with diabetic macular edema (DME). Two randomized, sham injection-controlled, double-masked, multicenter clinical trials. Subjects with persistent
John H Kempen et al.
Ophthalmology, 120(9), 1852-1859 (2013-05-28)
To evaluate agreement between fluorescein angiography (FA) and optical coherence tomography (OCT) results for diagnosis of macular edema in patients with uveitis. Multicenter cross-sectional study. Four hundred seventy-nine eyes with uveitis from 255 patients. The macular status of dilated eyes
Soraya Rofagha et al.
Ocular immunology and inflammation, 21(1), 77-78 (2013-01-18)
To describe a case of spontaneous dissociation of a fluocinolone acetonide implant (Retisert) 5 years following implantation. Case report. A patient with chronic uveitis underwent placement of a fluocinolone acetonide implant in the right eye in 2006. The patient's inflammation
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门